The Telegram channel carried a noteworthy message from the official distributor of an immunostimulant product. The communications came from Medical Corporation RHANA, the authorized representative for the drug Laennec in Russia, asserting that the original medication could not have caused the patient’s death.
According to RHANA, treatment protocols for this medication require a doctor’s prescription and supervision within polyclinics. The company emphasized a critical question: how did a young woman obtain the medication and how was it administered? They warned that counterfeit versions are circulating as demand for the product surges. RHANA stressed that the drug has no contraindications and cannot cause fatal outcomes when used appropriately under medical guidance.
Reports indicated that an event occurred in Moscow on March 27 involving a medical student whose life ended after consuming the immunity-boosting drug. A 22-year-old woman and her partner reportedly used the drug without a doctor’s prescription, raising concerns about access to the product and the risks associated with non-medical use. The incident has drawn the attention of authorities and health regulators who are reviewing the case.
Ongoing investigations are being conducted by the Investigative Committee of the Russian Federation and Roszdravnadzor. Officials are examining supply chains, patient history, and the circumstances surrounding how the drug was obtained and administered outside approved medical channels. Public health authorities emphasize the importance of using prescription medications only as directed by qualified healthcare professionals and warn against relying on non-prescribed sources or counterfeit versions that may be mislabeled or unsafe.
In the wake of the case, medical experts in North America and beyond reiterate the lessons for patients and caregivers: immunostimulants should be used with proper medical oversight, and the safety of any drug hinges on accurate dosing, correct administration, and reliable supply from legitimate providers. Regulators continue to monitor the situation, reinforce prescription controls, and communicate updates to clinicians and the public to minimize risk and prevent similar tragedies in the future.